PulseAugur
EN
LIVE 06:55:14

US pharma execs cautious on AI's drug success impact despite scaling adoption

By PulseAugur Editorial · [1 sources] ·

A recent survey indicates that while Chinese companies are actively adopting AI for drug discovery, only 24% of US pharmaceutical executives anticipate significant improvements in drug success rates from AI. Despite this cautious outlook, 72% of respondents reported that their companies are scaling or have fully scaled AI in R&D, with no companies planning to forgo the technology entirely. The study suggests that while AI could reduce global drug discovery costs by $26 billion, human biology and clinical judgment may remain significant bottlenecks. AI

IMPACT Highlights the gap between AI adoption and perceived impact on drug success rates, suggesting potential for cost savings but also persistent bottlenecks.

RANK_REASON Article discusses industry adoption trends and executive sentiment regarding AI in pharmaceuticals, rather than a specific event.

Read on SCMP — Tech →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

US pharma execs cautious on AI's drug success impact despite scaling adoption

How we ranked this

Signal score
5 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Commentary
Article discusses industry adoption trends and executive sentiment regarding AI in pharmaceuticals, rather than a specific event.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, policy
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Standard
On-topic for AI-industry coverage; kept in the public index.
Story freshness
Breaking (< 6h)
Fresh story with cross-source coverage still developing. Ranking may shift as more sources report.

Full methodology in our editorial standards.

COVERAGE [1]

  1. SCMP — Tech TIER_1 English(EN) · Julie Zhang ·

    As China embraces AI, only 24% of US pharma execs bet on it for drug-making

    Pharmaceutical companies have embraced artificial intelligence in drug research almost universally, yet few company executives expect AI to actually make drugs succeed, according to a Citi survey released on Tuesday. “The biggest risk to the AI-powered drug discovery thesis is no…

RELATED ENTITIES

RELATED TOPICS